Atezolizumab combined with targeted therapy improved median overall survival to 19 months in patients with anaplastic thyroid carcinoma (ATC). The longest survival was observed in the BRAF V600E ...

The following is a summary of “Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial,” ...

Our model utilized a tree-based decision analysis approach to simulate two different treatment strategies for metastatic cervical cancer: the standard bevacizumab plus platinum regimen, and the ...

The phase 1 dose-escalation portion of the Acclaim-3 trial (NCT05703971) evaluating quaratusugene ozeplasmid (Reqorsa) in combination with atezolizumab (Tecentriq) has successfully completed its 0.09 ...

A new combination therapy of lurbinectedin and atezolizumab showed promising results in improving overall survival and progression-free survival in extensive-stage small cell lung cancer.

The companies released positive top-line results from the Phase III clinical trial evaluating Zepzelca (lurbinectedin) in combination with the PD-L1 inhibitor Roche’s (ROG: SIX) atezolizumab ...